Published in Przegl Lek on January 01, 2011
Cutaneous viral infections in patients after kidney transplantation: risk factors. Pol Arch Med Wewn (2013) 2.03
Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol (2011) 1.09
Early detection of chronic kidney disease: results of the PolNef study. Am J Nephrol (2008) 0.92
Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant (2004) 0.91
Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn (2013) 0.90
Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis (2004) 0.88
Carpal tunnel syndrome in hemodialysis patients as a dialysis-related amyloidosis manifestation--incidence, risk factors and results of surgical treatment. Med Sci Monit (2011) 0.87
[Types of hemodialysis vascular access in patients on renal replacement therapy and its complications during a one year observation period]. Przegl Lek (2011) 0.85
Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Exp Nephrol (2011) 0.83
Relationship between aortic pulse wave velocity, selected proinflammatory cytokines, and vascular calcification parameters in peritoneal dialysis patients. J Hypertens (2014) 0.82
Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients. Biol Trace Elem Res (2007) 0.82
Clinical presentation of extraintestinal infections caused by non-typhoid Salmonella serotypes among patients at the University Hospital in Cracow during an 7-year period. Pol J Microbiol (2008) 0.82
Predicting kidney function from renal biopsy. Semiquantitative versus quantitative approach. Pol J Pathol (2007) 0.81
[Epidemiology of kidney diseases in Poland--pilot study (PolNef)]. Przegl Lek (2004) 0.80
[The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients]. Przegl Lek (2012) 0.78
Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal. Nucl Med Rev Cent East Eur (2004) 0.78
Interstitial, tubular and vascular factors in progression of primary glomerulonephritis. Pol J Pathol (2007) 0.78
[Coincidence of HCV and HGV infections in hemodialysis patients]. Przegl Lek (2010) 0.78
Transforming growth factor beta 1 as a risk factor for cardiovascular diseases in end-stage renal disease patients treated with peritoneal dialysis. Clin Lab (2014) 0.78
[Early diagnosis of renal diseases--preliminary results from the pilot study PolNef]. Przegl Lek (2005) 0.77
The influence of sodium profiling on blood volume and intradialytic hypotension in patients on maintenance hemodialysis. Przegl Lek (2007) 0.77
Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis. Med Sci Monit (2003) 0.77
Peritoneal solute transport rate as an independent risk factor for total and cardiovascular mortality in a population of peritoneal dialysis patients. Adv Perit Dial (2014) 0.77
[Cardiovascular calcification and five-years mortality in patients on maintenance hemodialysis]. Przegl Lek (2011) 0.77
Hemodialysis vascular access infection and mortality in maintenance hemodialysis patients. Przegl Lek (2011) 0.77
[Clinical usefulness of Nephral ST dialyzers in hemodialyzed patients with increased risk of bleeding]. Przegl Lek (2010) 0.76
[Influence of microinflammation and oxidative stress on atherosclerosis progression and calcifications in cardiovascular system of hemodialyzed patients during two years follow-up]. Przegl Lek (2007) 0.76
[Relapsing polychondritis--a challenge for modern diagnostics and treatment]. Przegl Lek (2008) 0.76
Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol Arch Med Wewn (2016) 0.76
Comment on "Cutaneous viral infections in patients after kidney transplantation: risk factors". Authors' reply. Pol Arch Med Wewn (2014) 0.75
[New measurement technics in biology and medicine: atomic force microscopy (part II)]. Przegl Lek (2004) 0.75
[Rapidly progressive ANCA-negative glomerulonephritis in the course of pauci immune microscopic vasculitis with hemolytic anemia probable in the course of Wilson's disease]. Przegl Lek (2011) 0.75
[Risk factors of non melanoma skin cancers in kidney transplant patients]. Przegl Lek (2014) 0.75
[Fibroblast growth factor-23 (FGF-23). Part III. Relationship between FGF-23 serum concentration and cardio-vascular morbidity and mortality]. Przegl Lek (2011) 0.75
[Merkel cell carcinoma in patient after organ transplantation]. Przegl Lek (2015) 0.75
[Factors predisposing to malnutrition development in the patients on maintenance hemodialysis]. Przegl Lek (2005) 0.75
[Clinical characteristic of patients with acute kidney injury complicated severe cardio-vascular diseases]. Przegl Lek (2016) 0.75
[GFR estimation based upon cystatin C concentration as a substance marker--proposal of a new formula]. Przegl Lek (2009) 0.75
[Fibroblast growth factor-23 (FGF-23). Part II. Significance in chronic kidney disease]. Przegl Lek (2011) 0.75
[Percutaneous renal denervation as a new method of treatment of resistant arterial hypertension]. Przegl Lek (2012) 0.75
[Influence of elevated homocystein level and selected lipid parameters in kidney transplant patients on the progression of atherosclerotic changes assessed by intima-media thickness index (CCA-IMT)]. Przegl Lek (2012) 0.75
[Post transplant lymphoprolipherative disorder (PTLD) in patients after kidney transplantation--clinical manifestation, treatment and prognosis]. Przegl Lek (2012) 0.75
[Lithium nephropathy]. Przegl Lek (2013) 0.75
[The role of kidney in pathogenesis of arterial hypertension]. Przegl Lek (2012) 0.75
[Outcome of patients with acute kidney injury in the course of neoplastic diseases]. Przegl Lek (2014) 0.75
Pentraxin3 as a new indicator of cardiovascular-related death in patients with advanced chronic kidney disease? Pol Arch Intern Med (2017) 0.75
[Comparison of the iron metabolism and effectiveness of anemia treatment in patients on maintenance hemodialysis performed based on polysulfone and helixone dialyzers]. Przegl Lek (2014) 0.75
[Pilot study of aluminum plasma level in healthy subjects in Poland]. Przegl Lek (2003) 0.75
[Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis]. Przegl Lek (2007) 0.75
[Electrophysiological diagnosis of severe carpal tunnel syndrome in patients on maintenance hemodialysis with created arterio-venous fistula and concomitant polyneuropathy]. Przegl Lek (2010) 0.75
[Fibroblast growth factor-23 (FGF-23). Part I. Significance in phosphate homeostasis and bone metabolism]. Przegl Lek (2011) 0.75
[Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis]. Przegl Lek (2002) 0.75
[Acute renal failure during HELLP syndrome--case report]. Przegl Lek (2004) 0.75
Cardiovascular risk in patients undergoing maintenance hemodialysis with Helixone® membrane: a multicenter randomized study. Pol Arch Med Wewn (2014) 0.75
Clinical consequences of nephrectomy performed on medical grounds. Przegl Lek (2014) 0.75
[Publishing activity of the Cracow Physicians Society]. Przegl Lek (2014) 0.75
[Nephropathy caused by radiocontrast media]. Przegl Lek (2005) 0.75
[Chronic kidney disease in the source documentation of the outpatient clinic Department of Nephrology. Part I. Causes of renal failure and characteristics of the studied population]. Przegl Lek (2009) 0.75
Hepatocyte growth factor as a long‑term predictor for total and cardiovascular mortality in patients on peritoneal dialysis. Pol Arch Med Wewn (2013) 0.75
[The relationship between serum soluble apoptosis marker (sTRAIL) concentration and nutritional parameters in hemodialyzed patients]. Przegl Lek (2013) 0.75
[New immune suppressants: topical immunomodulatory agents]. Przegl Lek (2002) 0.75
[Relationship between urine volume and long-term prognosis in patients with overcoming acute kidney injury (AKI)]. Przegl Lek (2009) 0.75
The evaluation of the effectiveness of multiple dose intradermal hepatitis B re-vaccination in hemodialyzed patients not responding to standard method of immunization. Przegl Lek (2007) 0.75
[Markers of inflammation and large artery compliance in patients with chronic renal failure]. Pol Merkur Lekarski (2006) 0.75
[Hundred-years-old patient on maintenance hemodialysis--case report]. Przegl Lek (2009) 0.75
Pentraxin 3 as a new indicator of cardiovascular‑related death in patients with advanced chronic kidney disease. Pol Arch Intern Med (2017) 0.75
[Chronic kidney disease (CKD) in source documentation of the outpatient clinic of the Department of Nephrology. Part III. CKD, comorbidities and performed surgical procedures]. Przegl Lek (2010) 0.75
[Comparison of the prevalence frequency of infectious skin changes in dialyzed patients and after kidney transplantation]. Przegl Lek (2013) 0.75
[Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment]. Przegl Lek (2010) 0.75
[New measurement techniques in biology and medicine: atomic force microscopy (part III)]. Przegl Lek (2004) 0.75
Coexistence of 2 malignant urogenital neoplasms: a testicular seminoma and adenocarcinoma of the prostate gland in a patient 1 year after kidney transplantation. Pol Arch Med Wewn (2016) 0.75
[Factors influencing on the prevalence frequency of infectious skin changes of bacterial and fungal origin in patients after kidney transplantation]. Przegl Lek (2013) 0.75
[Comparison of the hemodialysis adequacy conducted based on low-flux polysulfone dialyzers and high-flux helixone dialyzers]. Przegl Lek (2014) 0.75
Prevalence of the stages of chronic kidney disease (CKD) according to simplified MDRD formula in patients from ambulatory settings. Przegl Lek (2015) 0.75
[Evaluation of the interdependence between homocystein and folic acid levels in patients after kidney transplantation during a 2 year observation period]. Przegl Lek (2013) 0.75
[Disadvantages and benefits of early initiation of dialysotherapy]. Przegl Lek (2011) 0.75
[Chronic kidney disease in the source documentation of the outpatient clinic Department of Nephrology. Part II. Comparison of the three different methods of glomerular filtration rate estimation]. Przegl Lek (2009) 0.75
Effect of hemodialysis on acid leukocyte-type ribonuclease, alkaline ribonuclease and polymorphonuclear elastase serum levels in patients with end-stage renal disease. Nephron Clin Pract (2009) 0.75
[Activity of the Cracow Physicians Society concerning documentation and systematic strengthening of the memory of criminal genocides during World War II]. Przegl Lek (2013) 0.75
[Analysis of selected inflammatory markers in patients with stable renal graft (RTx) 36 months after transplantation]. Przegl Lek (2006) 0.75
[Post transplant lymphoproliferative disorder (PTLD)--10 years follow-up]. Przegl Lek (2011) 0.75
[Risk factors of death occurrence in patients with acute kidney injury in the course of severe cardio-vascular complications]. Przegl Lek (2016) 0.75
Location of nonmelanoma skin cancers in patients after kidney transplantation. Pol Arch Med Wewn (2014) 0.75
[Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment]. Przegl Lek (2010) 0.75
Abernethy malformation type I (congenital absence of the portal vein) in a patient with chronic kidney disease. Pol Arch Med Wewn (2016) 0.75
[Dialysis reinitiation after kidney transplant failure and preparation for retransplantation]. Przegl Lek (2015) 0.75
[Goodpasture's syndrome--disease of many faces]. Przegl Lek (2013) 0.75
[Erytrocyte membrane change due to the chemical treatment studied with atomic force microscopy]. Przegl Lek (2009) 0.75
[Ethical and legal issues concerning renal replacement therapy withdrawal or withholding]. Przegl Lek (2006) 0.75
[The new measurement technics in biology and medicine--atomic force microscopy]. Przegl Lek (2003) 0.75
[Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients]. Przegl Lek (2005) 0.75
[Hepatorenal syndrome]. Przegl Lek (2006) 0.75